Dupilumab's Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life.

IF 3.5 3区医学 Q2 IMMUNOLOGY

Journal of Immunology Research Pub Date : 2023-09-15 eCollection Date: 2023-01-01 DOI:10.1155/2023/4027701

Antonella Loperfido, Andrea Ciofalo, Carlo Cavaliere, Elona Begvarfaj, Francesca Cascone, Giacomo Alfonzo, Rosalba Cadeddu, Stefano Millarelli, Gianluca Bellocchi, Antonio Greco, Marco de Vincentiis, Simonetta Masieri

{"title":"Dupilumab's Impact on Blood Parameters in Nasal Polyposis: 18-Month Follow-Up in Real Life.","authors":"Antonella Loperfido, Andrea Ciofalo, Carlo Cavaliere, Elona Begvarfaj, Francesca Cascone, Giacomo Alfonzo, Rosalba Cadeddu, Stefano Millarelli, Gianluca Bellocchi, Antonio Greco, Marco de Vincentiis, Simonetta Masieri","doi":"10.1155/2023/4027701","DOIUrl":null,"url":null,"abstract":"Background: Dupilumab represents the first approved biological for severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP).Objective: Aim of this paper is to provide a multicentric real-life study about treatment with dupilumab for CRSwNP with a special focus on blood parameters and IgE, IgG, and IgA.Method: A retrospective data collection was jointly conducted at the Otolaryngology departments of San Camillo Forlanini Hospital and University of Rome \"La Sapienza\" from December 2020 to January 2023.Results: A total of 130 patients were included in the study. Monitoring our patients for 18 months, we observed a reduction in nasal polyposis and an improvement in symptoms and their impact on quality of life. Regarding blood tests, a transient increase in blood eosinophils was found in most cases. Total IgE showed a gradual decrease in values. IgG and IgA also showed a slight reduction of values, while remaining within normal ranges.Conclusion: To the best of our knowledge, this is the first study to evaluate the impact of dupilumab on several blood parameters in patients receiving treatment for CRswNP. Further studies are needed to confirm our results and to understand the underlying immunological mechanisms.","PeriodicalId":15952,"journal":{"name":"Journal of Immunology Research","volume":"2023 ","pages":"4027701"},"PeriodicalIF":3.5000,"publicationDate":"2023-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10516700/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Immunology Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1155/2023/4027701","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Dupilumab represents the first approved biological for severe uncontrolled chronic rhinosinusitis with nasal polyps (CRSwNP).

Objective: Aim of this paper is to provide a multicentric real-life study about treatment with dupilumab for CRSwNP with a special focus on blood parameters and IgE, IgG, and IgA.

Method: A retrospective data collection was jointly conducted at the Otolaryngology departments of San Camillo Forlanini Hospital and University of Rome "La Sapienza" from December 2020 to January 2023.

Results: A total of 130 patients were included in the study. Monitoring our patients for 18 months, we observed a reduction in nasal polyposis and an improvement in symptoms and their impact on quality of life. Regarding blood tests, a transient increase in blood eosinophils was found in most cases. Total IgE showed a gradual decrease in values. IgG and IgA also showed a slight reduction of values, while remaining within normal ranges.

Conclusion: To the best of our knowledge, this is the first study to evaluate the impact of dupilumab on several blood parameters in patients receiving treatment for CRswNP. Further studies are needed to confirm our results and to understand the underlying immunological mechanisms.

查看原文本刊更多论文

Dupilumab对鼻息肉病血液参数的影响：现实生活中18个月的随访。

背景：Dupilumab是首个被批准用于治疗严重非控制性慢性鼻窦炎伴鼻息肉（CRSwNP）的生物制剂。目的：本文的目的是提供一项关于杜匹单抗治疗CRSwNP的多中心真实研究，特别关注血液参数和IgE、IgG和IgA。方法：从2020年12月到2023年1月，在圣卡米洛-福拉尼尼医院和罗马大学“La Sapienza”的耳鼻咽喉科联合进行回顾性数据收集。结果：共有130名患者纳入研究。对我们的患者进行了18个月的监测，我们观察到鼻息肉病的减少、症状的改善及其对生活质量的影响。关于血液检查，在大多数情况下发现血液嗜酸性粒细胞短暂增加。总IgE值逐渐降低。IgG和IgA的值也略有下降，同时保持在正常范围内。结论：据我们所知，这是第一项评估杜匹单抗对接受CRswNP治疗的患者的几个血液参数影响的研究。需要进一步的研究来证实我们的结果并了解潜在的免疫机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Immunology Research IMMUNOLOGY-

CiteScore

6.90

自引率

2.40%

发文量

423

审稿时长

15 weeks

期刊介绍： Journal of Immunology Research is a peer-reviewed, Open Access journal that provides a platform for scientists and clinicians working in different areas of immunology and therapy. The journal publishes research articles, review articles, as well as clinical studies related to classical immunology, molecular immunology, clinical immunology, cancer immunology, transplantation immunology, immune pathology, immunodeficiency, autoimmune diseases, immune disorders, and immunotherapy.